Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GAPDH | P04406 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18271832 | 1.00 | ALDH1A1 (0.50) | ALDH1A1POLBGAAMAPK1NPSR1 | |
| SCHEMBL17685117 | 1.00 | ALDH1A1 (0.50) | ALDH1A1POLBGAAMAPK1NPSR1 | |
| SCHEMBL16556366 | 1.00 | ALDH1A1 (0.50) | ALDH1A1POLBGAAMAPK1NPSR1 | |
| SCHEMBL13424575 | 1.00 | ALDH1A1 (0.50) | ALDH1A1POLBGAAMAPK1NPSR1 | |
| SCHEMBL24371811 | 0.88 | ALDH1A1 (0.50) | ALDH1A1POLBGAAMAPK1NPSR1 | |
| SCHEMBL19326428 | 0.88 | ALDH1A1 (0.50) | ALDH1A1POLBGAAMAPK1NPSR1 | |
| SCHEMBL929484 | 0.88 | ALDH1A1 (0.50) | ALDH1A1POLBGAAMAPK1NPSR1 | |
| SCHEMBL17560666 | 0.88 | ALDH1A1 (0.50) | ALDH1A1POLBGAAMAPK1NPSR1 | |
| SCHEMBL21015462 | 0.88 | ALDH1A1 (0.50) | ALDH1A1POLBGAAMAPK1NPSR1 | |
| SCHEMBL19326334 | 0.88 | ALDH1A1 (0.50) | ALDH1A1POLBGAAMAPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3222628-A1 | NUCLEOSIDE PHOSPHORAMIDATES | Gilead Pharmasset LLC (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-2376088-B1 | 6-O-Substituted-2-amino-purine nucleoside phosphoramidates | GILEAD PHARMASSET LLC (US) | 2017-02-22 | — | — | EP | disclosed |
| US-9045520-B2 | Synthesis of purine nucleosides | GILEAD PHARMASSET LLC (US) | 2015-06-02 | — | — | US | disclosed |
| EP-2313422-B1 | NUCLEOSIDE CYCLICPHOSPHATES | GILEAD PHARMASSET LLC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8957045-B2 | Nucleoside phosphoramidates | GILEAD PHARMASSET LLC (US) | 2015-02-17 | — | — | US | disclosed |
| US-8759510-B2 | Nucleoside cyclicphosphates | GILEAD PHARMASSET LLC (US) | 2014-06-24 | — | — | US | disclosed |
| US-8716263-B2 | Synthesis of purine nucleosides | GILEAD PHARMASSET LLC (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716262-B2 | Nucleoside phosphoramidates | GILEAD PHARMASSET LLC (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2671888-A1 | 3',5'-cyclic nucleoside phosphate analogues | Gilead Pharmasset LLC (US) | 2013-12-11 | — | — | EP | disclosed |
| US-20130225519-A1 | NUCLEOSIDE PHOSPHORAMIDATES | GILEAD PHARMASSET LLC (US) | 2013-08-29 | — | — | US | disclosed |
| US-8173621-B2 | Nucleoside cyclicphosphates | GILEAD PHARMASSET LLC (US) | 2012-05-08 | — | — | US | disclosed |
| EP-2376515-A1 | Synthesis of purine nucleosides | Pharmasset, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-2376088-A2 | NUCLEOSIDE PHOSPHORAMIDATES | Pharmasset, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-2313422-A2 | NUCLEOSIDE CYCLICPHOSPHATES | Pharmasset, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20110015146-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-20100279973-A1 | SYNTHESIS OF PURINE NUCLEOSIDES | PHARMASSET, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| WO-2010075554-A1 | SYNTHESIS OF PURINE NUCLEOSIDES | PHARMASSET, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010075549-A2 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100081628-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PHARMASSET, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| WO-2009152095-A2 | NUCLEOSIDE CYCLICPHOSPHATES | PHARMASSET, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279973-A1 | SYNTHESIS OF PURINE NUCLEOSIDES | PNP, NUDT1, TYMP | ALDH1A1 2131/4885POLB 266/4885GAA 916/4885 |
| US-20110015146-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, TYMP, NUDT14 | ALDH1A1 2155/4885POLB 150/4885GAA 407/4885 |
| US-20100081628-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PNP, NUDT1, TYMP | ALDH1A1 3540/4885POLB 83/4885GAA 566/4885 |
| US-20130225519-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, TYMP, NUDT14 | ALDH1A1 2155/4885POLB 150/4885GAA 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.